Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

The Other Side Of Galena Biopharma
Seeking Alpha
Thursday, November 15, 2012 - 11:06am
tags:
Galena Biopharma
GlaxoSmithKline says FDA panel recommends approval of H5N1 flu vaccine
The Fly on the Wall
Thursday, November 15, 2012 - 10:57am
tags:
FDA, advisory panels, H5N1, vaccines, GSK
Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients
Bloomberg
Thursday, November 15, 2012 - 10:53am
tags:
GSK, Pfizer, HIV, Dolutegravir, Shionogi
How To Reach Those Hard-To-Reach Docs
Pharmalot
Thursday, November 15, 2012 - 10:50am
tags:
physicians, drug reps
Merck - How To Play This 'Patent Cliff' With Options
Seeking Alpha
Thursday, November 15, 2012 - 10:49am
tags:
patent cliff, Merck, Singulair, Odanacatib, Maxalt, MK-3475
Teva Is Still Healthier Than Its Big Pharma Peers
Seeking Alpha
Thursday, November 15, 2012 - 10:47am
tags:
Teva, AstraZeneca, Bristol-Myers Squibb, GSK, JNJ, Merck, Novo Nordisk, Novartis, Pfizer, Sanofi
Bristol-Myers, AstraZeneca Type 2 diabetes pill gets first major approval, in European Union
Yahoo/AP
Thursday, November 15, 2012 - 10:46am
tags:
diabetes, Bristol-Myers Squibb, AstraZeneca, Europe, SGLT2 inhibitor, Forxiga
Who Will Pioneer the New Diabetes Market?
Motley Fool
Thursday, November 15, 2012 - 10:45am
tags:
diabetes, JNJ, Merck, Bristol-Myers Squibb, AstraZeneca, SGLT2 inhibitor
3 Potential Partners for Amarin
Motley Fool
Thursday, November 15, 2012 - 10:43am
tags:
M&A, Amarin, AstraZeneca, Merck, Eli Lilly
Genzyme resolves shortage of cancer drug Thyrogen
Fierce Pharma
Wednesday, November 14, 2012 - 12:38pm
tags:
Thyrogen, Genzyme, thyroid cancer
The Stem Cell Sector Further Validates Itself With A Successful Q3
Seeking Alpha
Wednesday, November 14, 2012 - 12:37pm
tags:
stem cells, Osiris, NeoStem, Neuralstem, Aastrom Biosciences
All Is Well That Ends Well; Acquisition By Gilead Sciences Pays Off
Seeking Alpha
Wednesday, November 14, 2012 - 12:32pm
tags:
Gilead, M&A, hepatitis C
Celsion: Run-Up Trade Into Thermodox Results
TheStreet.com
Wednesday, November 14, 2012 - 12:31pm
tags:
Celsion, ThermoDox, liver cancer
Does Achillion Have a Place in the HCV Market of the Future?
Yahoo/Reuters
Wednesday, November 14, 2012 - 12:30pm
tags:
Achillion, hepatitis C, Abbott Labs, Gilead, ACH-1625, Vertex Pharmaceuticals
A Realistic View Of Belviq In The Short Term
Seeking Alpha
Wednesday, November 14, 2012 - 12:26pm
tags:
Belviq, obesity, Arena Pharmaceuticals
Jazz Pharmaceuticals falls after FDA denies petition
Yahoo/Fly on the Wall
Wednesday, November 14, 2012 - 12:25pm
tags:
FDA, Jazz Pharmaceuticals
Palatin Investors Prepared For The Long Haul With Another FSD Drug
Seeking Alpha
Wednesday, November 14, 2012 - 12:25pm
tags:
Palatin, FSD, bremelanotide
Anthera's Lupus Drug Gets Second Chance After Clinical Trial Disaster
Seeking Alpha
Wednesday, November 14, 2012 - 12:14pm
tags:
Anthera, lupus, blisibimod
Can You Profit From 4 Big Pharmas Making Headlines?
Motley Fool
Wednesday, November 14, 2012 - 11:30am
tags:
Abbott Labs, JNJ, Merck, Pfizer
'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production
Seeking Alpha
Wednesday, November 14, 2012 - 11:13am
tags:
Novavax, Flu, vaccines, GSK, Merck, Novartis, Sanofi

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.